Cannabis stocks surge on rescheduling news; Aurora Cannabis jumps 16% despite no US strategy. Read why I'm maintaining my ...

Aurora Cannabis posted mixed Q1 FY2026 results, facing sales pressure, covenant issues, and looming German regulatory risks.

Canopy Growth (CGC), Cronos Group (CRON) and Trulieve Cannabis (TCNNF) after reports that U.S. President Donald Trump may ...

U.S. President Donald Trump’s administration is looking to reclassify marijuana as a less dangerous drug, a shift that could ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Greetings and welcome to Aurora Cannabis Incorporated Fiscal First Quarter 2026 Results Conference Call all participants will ...

However, Aurora Cannabis is no Apple: There is very little reason to think the pot grower can reverse course. First, the problems it faced in the Canadian cannabis market largely remain.

When recreational cannabis was legalized, the city of Aurora decided dispensary hours should be 8 a.m. to 10 p.m. "The hype is still there, people are still consuming," said Starbuds Store ...

Aurora sold about $15 million of adult-use cannabis in the quarter, while rival Canopy Growth sold about $47.3 million, a 35% increase from the same period of 2020.

Aurora Cannabis' problems continue to mount. Earlier this week, the company announced that it had fully completed a $250 million (that's U.S.) at-the-market (ATM) offering first announced in April.

Cannabis derivatives could be a key market for Aurora to rebound For the quarter ended Sept. 30, Aurora's total cannabis net revenue sank 8% year over year to 67.8 million Canadian dollars.